We observed that the combined inhibition of Hh and PI3K/Akt/mTOR signaling exerts a synergistic anti-leukemic effect, thereby underscoring the potential of this therapeutic strategy in T-ALL. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.